Current landscape of risk stratification and adjuvant trials for high-risk localized kidney cancer. TNM, tumor node metastasis classification; UISS, University of California Los Angeles Integrated Staging System; MSK, Memorial Sloan Kettering; SSIGN, stage size grade necrosis; IFN-α, interferon-α; HD IL-2, high-dose interleukin-2; VEGF, vascular endothelial growth factor; mTOR, mammalian target of rapamycin; ADCC, antibody-dependent cellular cytotoxic; CAIX, carbonic anhydrase IX.